Caribou Biosciences Inc

NASDAQ CRBU

Data sourced from iex and EODHD
Download Data

Caribou Biosciences Inc Beginning Cash 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: -12.37%

Caribou Biosciences Inc Beginning Cash 1 year YoY Change (%) is -12.37% for the Trailing 12 Months (TTM) ending March 31, 2024, a 83.66% change year over year. Beginning Cash is the amount of cash held by a company at the beginning of a specific period. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Caribou Biosciences Inc Beginning Cash for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 58.38 M, a -75.72% change year over year.
  • Caribou Biosciences Inc Beginning Cash for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 240.47 M, a 1,407.34% change year over year.
  • Caribou Biosciences Inc Beginning Cash for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 15.95 M, a -61.16% change year over year.
  • Caribou Biosciences Inc Beginning Cash for the Trailing 12 Months (TTM) ending March 31, 2020 was USD 41.07 M.
NASDAQ: CRBU

Caribou Biosciences Inc

CEO Dr. Rachel E. Haurwitz Ph.D.
IPO Date July 23, 2021
Location United States
Headquarters 2929 7th Street, Berkeley, CA, United States, 94710
Employees 158
Sector Healthcare
Industry Biotechnology
Description

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

StockViz Staff

September 20, 2024

Any question? Send us an email